These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33176437)

  • 61. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
    Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
    Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of l-arginine on cardiac reverse remodeling and quality of life in patients with heart failure.
    Salmani M; Alipoor E; Navid H; Farahbakhsh P; Yaseri M; Imani H
    Clin Nutr; 2021 May; 40(5):3037-3044. PubMed ID: 33610421
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
    Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
    J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.
    Shen YT; Malik FI; Zhao X; Depre C; Dhar SK; Abarzúa P; Morgans DJ; Vatner SF
    Circ Heart Fail; 2010 Jul; 3(4):522-7. PubMed ID: 20498236
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
    Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Abraham WT; Ponikowski P; Brueckmann M; Zeller C; Macesic H; Peil B; Brun M; Ustyugova A; Jamal W; Salsali A; Lindenfeld J; Anker SD;
    Eur J Heart Fail; 2019 Jul; 21(7):932-942. PubMed ID: 31218819
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure.
    Clark AL; Johnson M; Fairhurst C; Torgerson D; Cockayne S; Rodgers S; Griffin S; Allgar V; Jones L; Nabb S; Harvey I; Squire I; Murphy J; Greenstone M
    Health Technol Assess; 2015 Sep; 19(75):1-120. PubMed ID: 26393373
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Novel Trial Design: CHIEF-HF.
    Spertus JA; Birmingham MC; Butler J; Lingvay I; Lanfear DE; Abbate A; Kosiborod ML; Fawcett C; Burton P; Damaraju CV; Januzzi JL; Whang J
    Circ Heart Fail; 2021 Mar; 14(3):e007767. PubMed ID: 33724883
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
    Borlaug BA; Anstrom KJ; Lewis GD; Shah SJ; Levine JA; Koepp GA; Givertz MM; Felker GM; LeWinter MM; Mann DL; Margulies KB; Smith AL; Tang WHW; Whellan DJ; Chen HH; Davila-Roman VG; McNulty S; Desvigne-Nickens P; Hernandez AF; Braunwald E; Redfield MM;
    JAMA; 2018 Nov; 320(17):1764-1773. PubMed ID: 30398602
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model.
    Wu SN; Tsai MS; Huang CH; Chen WJ
    PLoS One; 2022; 17(2):e0264165. PubMed ID: 35176110
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE).
    St John Sutton M; Cerkvenik J; Borlaug BA; Daubert C; Gold MR; Ghio S; Chirinos JA; Linde C; Ky B
    J Am Heart Assoc; 2015 Sep; 4(9):e002054. PubMed ID: 26363005
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.
    Butler J; Stebbins A; Melenovský V; Sweitzer NK; Cowie MR; Stehlik J; Khan MS; Blaustein RO; Ezekowitz JA; Hernandez AF; Lam CSP; Nkulikiyinka R; O'Connor CM; Pieske BM; Ponikowski P; Spertus JA; Voors AA; Anstrom KJ; Armstrong PW;
    Circ Heart Fail; 2022 Jun; 15(6):e009337. PubMed ID: 35656822
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
    Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Comin-Colet J; Ferreira JP; Mentz RJ; Nassif ME; Psotka MA; Tromp J; Brueckmann M; Blatchford JP; Salsali A; Voors AA
    Circulation; 2022 Jul; 146(4):279-288. PubMed ID: 35377706
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
    JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
    Van Tassell BW; Canada J; Carbone S; Trankle C; Buckley L; Oddi Erdle C; Abouzaki NA; Dixon D; Kadariya D; Christopher S; Schatz A; Regan J; Viscusi M; Del Buono M; Melchior R; Mankad P; Lu J; Sculthorpe R; Biondi-Zoccai G; Lesnefsky E; Arena R; Abbate A
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141858
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF).
    Biering-Sørensen T; Minamisawa M; Liu J; Claggett B; Papolos AI; Felker GM; McMurray JJV; Legg JC; Malik FI; Honarpour N; Kurtz CE; Teerlink JR; Solomon SD
    Eur J Heart Fail; 2021 Jun; 23(6):1052-1056. PubMed ID: 33826209
    [No Abstract]   [Full Text] [Related]  

  • 77. Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices.
    Snipelisky D; Kelly J; Levine JA; Koepp GA; Anstrom KJ; McNulty SE; Zakeri R; Felker GM; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2017 Jun; 10(6):e003878. PubMed ID: 28588021
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
    Han SW; Choi SW; Ryu KH; Kim HJ; Kim SH; Shim WJ; Cha TJ; Choi DJ; Kim YJ; Yoo BS; Kim JH; Hwang KK; Jeon H; Shin MS
    Cardiovasc Ther; 2016 Jun; 34(3):172-9. PubMed ID: 27003232
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction.
    Zamani P; Tan V; Soto-Calderon H; Beraun M; Brandimarto JA; Trieu L; Varakantam S; Doulias PT; Townsend RR; Chittams J; Margulies KB; Cappola TP; Poole DC; Ischiropoulos H; Chirinos JA
    Circ Res; 2017 Mar; 120(7):1151-1161. PubMed ID: 27927683
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
    Voors AA; Bax JJ; Hernandez AF; Wirtz AB; Pap AF; Ferreira AC; Senni M; van der Laan M; Butler J;
    Eur J Heart Fail; 2019 Nov; 21(11):1426-1433. PubMed ID: 31523892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.